Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 856 to 870 of 1331 results for heart OR cardi* OR arrythmia

  1. Prucalopride for the treatment of chronic constipation in women (TA211)

    Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA211

  2. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

    Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.

    Technology appraisal guidance
    Published
    24 January 2007
    View recommendations

    Sections for TA117

  3. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

    Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Last updated
    1 January 2012
    View recommendations

    Sections for TA118

  4. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA682

  5. Bosutinib for previously treated chronic myeloid leukaemia (TA401)

    Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA401

  6. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA346

  7. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Last updated
    23 November 2016
    View recommendations

    Sections for TA288

  8. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

    Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA451

  9. Drug-eluting stents for the treatment of coronary artery disease (TA152)

    Evidence-based recommendations on using drug-eluting stents in adults.

    Technology appraisal guidance
    Last updated
    18 November 2020
    View recommendations

    Sections for TA152

  10. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA461

  11. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Published
    6 September 2017
    View recommendations

    Sections for TA474

  12. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

    Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.

    Technology appraisal guidance
    Published
    24 February 2016
    View recommendations

    Sections for TA385

  13. Antiplatelet therapy: For people with CKD at the highest risk of cardiovascular disease, what is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of cardiovascular disease?

    risk of cardiovascular disease, what is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of...

    Research recommendation
    Published
    30 September 2021

  14. Long-term complications of spondyloarthritis:- What is the incidence of long-term complications, in particular osteoporosis, cardiovascular disease (CVD) and metabolic syndrome, in people with spondyloarthritis, and how does this compare with the general population? Are any specific spondyloarthritis features or risk factors associated with the incidence and outcomes of these complications?

    the incidence of long-term complications, in particular osteoporosis, cardiovascular disease (CVD) and metabolic syndrome, in people...

    Research recommendation
    Published
    4 May 2017

  15. Blood pressure targets for people aged over 80: What is the optimum blood pressure target for people aged over 80 with treated primary hypertension (with or without cardiovascular disease)?

    people aged over 80 with treated primary hypertension (with or without cardiovascular disease)? Any explanatory notes(if applicable) For...

    Research recommendation
    Published
    11 April 2022